# Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

> **NCT04445987** · PHASE2 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 408 (actual)

## Conditions studied

- Seborrheic Dermatitis

## Interventions

- **DRUG:** ARQ-154

## Key facts

- **NCT ID:** NCT04445987
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-12
- **Primary completion:** 2022-11-19
- **Final completion:** 2022-11-19
- **Target enrollment:** 408 (ACTUAL)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445987, "Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04445987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*